Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit

September 29, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27

September 29, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Animal Health Completes Minority Investment in LeeO Precision Farming

September 27, 2022

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

September 27, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Animal Health to Acquire Vence

September 22, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer

September 22, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

September 20, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children

September 16, 2022

From Merck & Co., Inc.

Via Business Wire

Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)

September 11, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

September 10, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials

September 09, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 06, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Reports Strong Progress in ESG Focus Areas

August 30, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer

August 29, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer

August 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy

August 23, 2022

From Merck & Co., Inc.

Via Business Wire

FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

August 16, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

August 16, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

August 04, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

August 03, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

August 03, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Second-Quarter 2022 Financial Results

July 28, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Fourth-Quarter 2022 Dividend

July 26, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma

July 20, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer

July 13, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market

June 29, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28

June 29, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

June 27, 2022

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection

June 24, 2022

From Merck & Co., Inc.

Via Business Wire

CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children

June 22, 2022

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Merck & Co., Inc.

Starting at /week.